Leap Therapeutics 将来の成長

Future 基準チェック /06

Leap Therapeuticsは、5.2%と83.6%でそれぞれ年率5.2%で利益と収益が成長すると予測される一方、EPSはgrowで17.5%年率。

主要情報

5.2%

収益成長率

17.5%

EPS成長率

Biotechs 収益成長	36.2%
収益成長率	83.6%
将来の株主資本利益率	n/a
アナリストカバレッジ	Low
最終更新日	13 Aug 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

DB:5MC - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	2	-60	-67	N/A	4
12/31/2025	N/A	-56	-56	N/A	4
12/31/2024	N/A	-68	-66	N/A	4
6/30/2024	N/A	-60	-50	-50	N/A
3/31/2024	N/A	-53	-47	-47	N/A
12/31/2023	N/A	-81	-45	-44	N/A
9/30/2023	N/A	-81	-48	-46	N/A
6/30/2023	N/A	-82	-50	-48	N/A
3/31/2023	N/A	-86	-51	-50	N/A
12/31/2022	N/A	-55	-49	-49	N/A
9/30/2022	0	-53	-47	-47	N/A
6/30/2022	1	-49	-43	-43	N/A
3/31/2022	1	-42	-38	-38	N/A
12/31/2021	2	-41	-35	-35	N/A
9/30/2021	2	-37	-30	-30	N/A
6/30/2021	2	-32	-29	-29	N/A
3/31/2021	2	-29	-31	-31	N/A
12/31/2020	2	-38	-26	-26	N/A
9/30/2020	1	-39	-26	-26	N/A
6/30/2020	1	-40	-26	-26	N/A
3/31/2020	0	-42	-24	-24	N/A
12/31/2019	N/A	-33	-27	-27	N/A
9/30/2019	N/A	-24	-28	-28	N/A
6/30/2019	N/A	-22	-29	-29	N/A
3/31/2019	N/A	-21	-27	-27	N/A
12/31/2018	N/A	-23	-26	-26	N/A
9/30/2018	N/A	-31	-25	-25	N/A
6/30/2018	N/A	-31	-20	-20	N/A
3/31/2018	N/A	-31	N/A	-21	N/A
12/31/2017	N/A	-30	N/A	-22	N/A
9/30/2017	N/A	-29	N/A	-23	N/A
6/30/2017	N/A	-30	N/A	-28	N/A
3/31/2017	N/A	-30	N/A	-28	N/A
12/31/2016	N/A	-26	N/A	-25	N/A
9/30/2016	N/A	-23	N/A	-21	N/A
6/30/2016	N/A	-19	N/A	-15	N/A
3/31/2016	N/A	-14	N/A	-11	N/A
12/31/2015	N/A	-12	N/A	-8	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 5MC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 5MC今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 5MC今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 5MC来年は収益がないと予測されています。

高い収益成長: 5MC来年は収益がないと予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 5MCの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Leap Therapeutics 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Recent updates

Leap Therapeutics, Inc. Announces Completion of Enrollment in Part B of the DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics, Inc., Annual General Meeting, Jul 02, 2024

Leap Therapeutics, Inc. announced that it expects to receive $39.998476 million in funding from Samsara BioCapital LLC, 683 Capital Management, LLC, Rock Springs Capital Management LP, Gilead Sciences, Inc., Laurion Capital Management LP

Leap Therapeutics, Inc. to Present New Clinical Data from Part A of Defiance Study At the 2024 Asco Gastrointestinal Cancers Symposium

Leap Therapeutics, Inc. Announces Completion of Enrollment in Randomized Controlled Part C of the Distinguish Study of DKN-01 for the Treatment of Gastric Cancer Patients

Leap Therapeutics, Inc. Announces Initiation of Randomized Controlled Part B of the Defiance Study of DKN-01 in Colorectal Cancer Patients

Leap Therapeutics Announces Reverse Stock Split to Meet the Minimum Nasdaq Listing Price Per Share Requirements

Leap Therapeutics to Present Updated Data from Part A of the DisTinGuish Study of DKN-01 Plus Tislelizumab and Chemotherapy in Gastric Cancer Patients at the 2023 ASCO Annual Meeting

Leap Therapeutics, Inc. (NasdaqGM:LPTX) acquired Flame Biosciences, Inc from Acuta Capital Partners LLC, Adage Capital Management, L.P., Cormorant Asset Management, LP, Cormorant Asset Management, LP, Terra Magnum Capital Partners and others.

Leap Therapeutics, Inc. Appoints Atricia Martin and Christian Richard to Board of Directors

Third quarter 2022 earnings released: US$0.13 loss per share (vs US$0.14 loss in 3Q 2021)

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces First Patient Enrolled in Defiance Study of Dkn-01 for the Treatment of Colorectal Cancer Patients

Leap Therapeutics Announces First Patient Enrolled in Part C of Phase 2 Distinguish Study of DKN-01 in Combination with Tislelizumab for the Treatment of Gastric or Gastroesophageal Junction Cancer

Leap Therapeutics to Present Updated Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab and Preclinical Data in Colorectal Cancer Models at the SITC Annual Meeting

Leap Therapeutics, Inc. Announces Appointment of Richard L. Schilsky, MD to its Board of Directors

Leap Therapeutics to Present New Data from DisTinGuish Study of DKN-01 Plus Tislelizumab and WAKING Study of DKN-01 Plus Tecentriq at the ESMO Congress

First half 2022 earnings released

Leap Therapeutics, Inc. Resigns Dr. Monica Bertagnolli, as Director

Leap Therapeutics and BeiGene, Ltd. Announces Initiation of New DKN-01 Clinical Trials in Gastric Cancer, Colorectal Cancer and Endometrial Cancer

Leap Therapeutics, Inc. to Present Initial Data from the Investigator-Sponsored Study of DKN-01 Plus Docetaxel in Patients with Prostate Cancer at the 2022 ASCO Annual Meeting

First quarter 2022 earnings released: US$0.092 loss per share (vs US$0.12 loss in 1Q 2021)

Insufficient new directors

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Leap Therapeutics to Present Positive New Data from the Distinguish Study of DKN-01 Plus Tislelizumab at the Asco GI Cancers Symposium

Insufficient new directors

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.092 loss in 3Q 2020)

Leap Therapeutics to Present New Data from the Distinguish Study of Dkn-01 Plus Tislelizumab At the Esmo 2021 Congress

First half 2021 earnings released: US$0.24 loss per share (vs US$0.57 loss in 1H 2020)

First quarter 2021 earnings released: US$0.12 loss per share (vs US$0.55 loss in 1Q 2020)

Leap Therapeutics, Inc. Provides DKN-01 Development Update

Revenue misses expectations

New 90-day high: €2.18

New 90-day high: €2.00

New 90-day low: €1.27

Leap Therapeutics, Inc. Announces the Presentation of Clinical Data from Its Phase 1b/2a Clinical Trial of DKN-01 in Patients with Advanced Esophagogastric Cancer

New 90-day high: €1.84

Leap Therapeutics, Inc. announced that it has received $26.985796 million in funding from Perceptive Advisors LLC, BeiGene, Ltd., Baker Bros. Advisors LP

Leap Therapeutics, Inc. Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer

Leap Therapeutics and Beigene Announces First Patient Dosed in Study of DKN-01 in Combination with Tislelizumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Cancer

New 90-day low - €1.50

New 90-day low - €1.52

Leap Therapeutics, Inc.(NasdaqGM:LPTX) dropped from Russell Microcap Value Index

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘